Assembly Biosciences (ASMB) closed at $21.79 on November 9, 2026, up 6.7% from the previous close, on volume of 302,284 shares (30-day average 226,767).
Data as of November 9, 2026.
Assembly Biosciences to Participate in Upcoming Investor Conferences
Globe Newswire (Mon, 2-Nov 4:00 PM ET)
Globe Newswire (Thu, 29-Oct 4:00 PM ET)
Globe Newswire (Mon, 5-Oct 10:00 AM ET)
Globe Newswire (Thu, 10-Sep 4:15 PM ET)
Globe Newswire (Tue, 8-Sep 4:00 PM ET)
Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates
Globe Newswire (Thu, 13-Aug 4:00 PM ET)
Market Chameleon (Fri, 20-Mar 5:59 AM ET)
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
Assembly Biosciences trades on the NASDAQ stock market under the symbol ASMB.
As of November 10, 2026, ASMB stock price declined to $21.23 with 149,567 million shares trading.
ASMB has a beta of 0.87, meaning it tends to be less sensitive to market movements. ASMB has a correlation of 0.04 to the broad based SPY ETF.
ASMB has a market cap of $432.26 million. This is considered a Small Cap stock.
Last quarter Assembly Biosciences reported $13 million in Revenue and -$.20 earnings per share. This beat revenue expectation by $6 million and exceeded earnings estimates by $.36.
In the last 3 years, ASMB traded as high as $39.71 and as low as $7.69.
The top ETF exchange traded funds that ASMB belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWN.
ASMB has underperformed the market in the last year with a return of -32.0%, while the SPY ETF gained +12.8%. In the last 3 month period, ASMB fell short of the market, returning -20.4%, while SPY returned -2.9%. However, in the most recent 2 weeks ASMB has outperformed the stock market by returning +7.9%, while SPY returned -2.1%.
ASMB support price is $20.90 and resistance is $22.68 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ASMB shares will trade within this expected range on the day.
